AR102595A1 - Anticuerpos anti-ang2 y métodos de utilización - Google Patents

Anticuerpos anti-ang2 y métodos de utilización

Info

Publication number
AR102595A1
AR102595A1 ARP150103648A ARP150103648A AR102595A1 AR 102595 A1 AR102595 A1 AR 102595A1 AR P150103648 A ARP150103648 A AR P150103648A AR P150103648 A ARP150103648 A AR P150103648A AR 102595 A1 AR102595 A1 AR 102595A1
Authority
AR
Argentina
Prior art keywords
amino acid
antibody
sequence seq
variable domain
acid residue
Prior art date
Application number
ARP150103648A
Other languages
English (en)
Spanish (es)
Inventor
Molhoj Michael
Moelleken Joerg
Thomas Regula Joerg
Kettenberger Hubert
Georges Guy
Michael Huelsmann Peter
Dengl Stefan
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR102595A1 publication Critical patent/AR102595A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ARP150103648A 2014-11-10 2015-11-09 Anticuerpos anti-ang2 y métodos de utilización AR102595A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14192524 2014-11-10

Publications (1)

Publication Number Publication Date
AR102595A1 true AR102595A1 (es) 2017-03-08

Family

ID=51868115

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150103648A AR102595A1 (es) 2014-11-10 2015-11-09 Anticuerpos anti-ang2 y métodos de utilización

Country Status (14)

Country Link
US (1) US10538585B2 (index.php)
EP (1) EP3218398A1 (index.php)
JP (2) JP2017534644A (index.php)
KR (1) KR20170082594A (index.php)
CN (1) CN107001456A (index.php)
AR (1) AR102595A1 (index.php)
AU (1) AU2015345321A1 (index.php)
BR (1) BR112017009790A2 (index.php)
CA (1) CA2963606A1 (index.php)
IL (1) IL251477A0 (index.php)
MX (1) MX2017005642A (index.php)
SG (1) SG11201703458UA (index.php)
TW (1) TW201630935A (index.php)
WO (1) WO2016075035A1 (index.php)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2417156B1 (en) 2009-04-07 2015-02-11 Roche Glycart AG Trivalent, bispecific antibodies
CN107074941A (zh) 2014-11-10 2017-08-18 豪夫迈·罗氏有限公司 双特异性抗体和用于眼科学的方法
WO2016075036A1 (en) 2014-11-10 2016-05-19 F. Hoffmann-La Roche Ag Anti-pdgf-b antibodies and methods of use
JP6787888B2 (ja) 2014-11-10 2020-11-18 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 抗ｉｌ−１ベータ抗体及び使用方法
JP6721590B2 (ja) 2014-12-03 2020-07-15 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 多重特異性抗体
EP3728327A1 (en) 2017-12-22 2020-10-28 F. Hoffmann-La Roche AG Depletion of light chain mispaired antibody variants by hydrophobic interaction chromatography
WO2019164219A1 (en) * 2018-02-20 2019-08-29 Institute For Basic Science Anti-angiopoietin-2 antibodies and uses thereof
KR102497171B1 (ko) 2018-02-20 2023-02-08 기초과학연구원 항-안지오포이에틴-2(Ang2) 항체 및 그의 용도
CN115734971A (zh) 2020-06-22 2023-03-03 信达生物制药(苏州)有限公司 抗ang-2抗体及其用途
EP4192861A4 (en) * 2020-08-07 2025-01-08 Nanjing GenScript Biotech Co., Ltd. Antibodies against human angiopoietin-2 and uses thereof
KR20220022878A (ko) * 2020-08-19 2022-02-28 주식회사 파멥신 변형 항체 및 이의 제조방법
CN115772544B (zh) * 2021-09-06 2024-04-26 合肥星眸生物科技有限公司 抗vegf-a和ang-2的aav载体
CN116925234B (zh) * 2022-04-02 2024-05-31 合肥星眸生物科技有限公司 一种编码抗vegf-a和ang-2双特异性抗体的aav载体
CN117820490A (zh) * 2022-09-28 2024-04-05 科兴生物制药股份有限公司 Vegf和ang-2双特异性抗体及其应用

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4935343A (en) 1986-08-08 1990-06-19 Syntex (U.S.A.) Inc. Monoclonal antibodies for interleukin-1β
GB0020685D0 (en) 2000-08-22 2000-10-11 Novartis Ag Organic compounds
EP1481010A2 (en) 2002-02-28 2004-12-01 Eli Lilly And Company Anti-interleukin-1 beta analogs
AU2003244817B2 (en) * 2002-06-28 2010-08-26 Domantis Limited Antigen-binding immunoglobulin single variable domains and dual-specific constructs
MXPA05007853A (es) 2003-01-24 2006-02-10 Applied Molecular Evolution Antagonistas de il-1 beta humana.
WO2005087812A1 (en) 2004-03-05 2005-09-22 Ludwig Institute For Cancer Research Multivalent antibody materials and methods for vegf/pdgf family of growth factors
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
AR059066A1 (es) * 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
KR20100017514A (ko) 2007-05-07 2010-02-16 메디뮨 엘엘씨 항 ｉｃｏｓ 항체, 및 종양, 이식 및 자가면역성 질환 치료에서의 이의 용도
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
JO2913B1 (en) * 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
US20110189172A1 (en) 2008-06-06 2011-08-04 Xoma Technology, Ltd. Methods for the treatment of rheumatoid arthritis
RU2368359C1 (ru) 2008-07-22 2009-09-27 Государственное учреждение "УФИМСКИЙ НАУЧНО-ИССЛЕДОВАТЕЛЬСКИЙ ИНСТИТУТ ГЛАЗНЫХ БОЛЕЗНЕЙ" Академии наук Республики Башкортостан (УфНИИ ГБ АН РБ) Способ лечения возрастной макулярной дегенерации
US8268314B2 (en) * 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
US8133979B2 (en) * 2008-12-16 2012-03-13 Hoffmann-La Roche Inc. Antibodies against human angiopoietin 2
AR080794A1 (es) 2010-03-26 2012-05-09 Hoffmann La Roche Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2
BR112013003279A2 (pt) 2010-08-13 2016-06-14 Genentech In “métodos para tratar uma doença, método para neutralizar ou bloquear a atividade de il-1ß e/ou il-18, anticorpo, usos de um anticorpo e usos de um anticorpo monoclonal”
JP5866130B2 (ja) 2010-09-10 2016-02-17 アペクシジェン， インコーポレイテッド 抗ＩＬ−１β抗体およびその使用方法
CA2830254C (en) 2011-03-16 2019-09-10 Amgen Inc. Fc variants
CA2840212A1 (en) * 2011-06-29 2013-01-03 Amgen Inc. Predictive biomarker of survival in the treatment of renal cell carcinoma
KR20150023957A (ko) 2012-06-28 2015-03-05 몰리큘라 파트너스 아게 혈소판-유래 성장인자에 결합하는 설계된 안키린 반복 단백질
DK3495387T3 (da) * 2012-07-13 2021-11-08 Roche Glycart Ag Bispecifikke anti-VEGF-/anti-ANG-2-antistoffer og deres anvendelse ved behandling af okulære vaskulære sygdomme
US20140093499A1 (en) * 2012-09-28 2014-04-03 Boehringer Ingelheim International Gmbh Pharmaceutical combinations comprising dual angiopoietin-2 / dll4 binders and anti-vegf agents
BR112015006363A2 (pt) * 2012-09-28 2017-08-08 Boehringer Ingelheim Int combinações farmacêuticas compreendendo ligantes angiopoietina-2/dll4 duplos e agentes anti-vegf-r
WO2014074823A1 (en) 2012-11-08 2014-05-15 Clearside Biomedical, Inc. Methods and devices for the treatment of ocular diseases in human subjects
KR20150082503A (ko) 2012-11-09 2015-07-15 화이자 인코포레이티드 혈소판 유래 성장 인자 b 특이적 항체, 및 그의 조성물 및 용도
JO3405B1 (ar) 2013-01-09 2019-10-20 Regeneron Pharma الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
PE20151807A1 (es) * 2013-04-29 2015-12-02 Hoffmann La Roche Anticuerpos modificados de union a fcrn humano y metodo de utilizacion
MX2016008099A (es) * 2013-12-20 2016-10-13 Hoffmann La Roche Terapia combinada con un anticuerpo anti-ang2 y un agonista de cd40.
CA2931986A1 (en) * 2014-01-15 2015-07-23 F. Hoffmann-La Roche Ag Fc-region variants with modified fcrn- and maintained protein a-binding properties
CN107074941A (zh) * 2014-11-10 2017-08-18 豪夫迈·罗氏有限公司 双特异性抗体和用于眼科学的方法
JP6787888B2 (ja) 2014-11-10 2020-11-18 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 抗ｉｌ−１ベータ抗体及び使用方法
WO2016075036A1 (en) 2014-11-10 2016-05-19 F. Hoffmann-La Roche Ag Anti-pdgf-b antibodies and methods of use
WO2016209972A1 (en) * 2015-06-26 2016-12-29 Amgen Inc. Biomarker of survival in the treatment of renal cell carcinoma with a vegfr inhibitor and an ang2 inhibitor
BR112019022074A2 (pt) * 2017-06-02 2020-05-12 Boehringer Ingelheim International Gmbh Terapia de combinação anticâncer

Also Published As

Publication number Publication date
IL251477A0 (en) 2017-05-29
EP3218398A1 (en) 2017-09-20
WO2016075035A1 (en) 2016-05-19
CA2963606A1 (en) 2016-05-19
JP2021050229A (ja) 2021-04-01
SG11201703458UA (en) 2017-05-30
US20170247441A1 (en) 2017-08-31
BR112017009790A2 (pt) 2017-12-19
KR20170082594A (ko) 2017-07-14
MX2017005642A (es) 2017-07-24
US10538585B2 (en) 2020-01-21
CN107001456A (zh) 2017-08-01
TW201630935A (zh) 2016-09-01
JP2017534644A (ja) 2017-11-24
AU2015345321A1 (en) 2017-04-20

Similar Documents

Publication Publication Date Title
AR102595A1 (es) Anticuerpos anti-ang2 y métodos de utilización
PE20190975A1 (es) Novela cd47 anticuerpos monoclonales y sus usos
AR099698A1 (es) Anticuerpos contra el c5 que tienen farmacocinética mejorada
EA201791168A1 (ru) Способы и составы для лечения сосудистых заболеваний глаз
CO2020014180A2 (es) Derivados de gip y usos de estos
AR105313A1 (es) Anticuerpo anti-cd137 terapéutico
GEAP202114720A (en) Constructs having a sirp-alpha domain or variant thereof
CO2017009954A2 (es) Dominios diseñados con repeticiones de anquirina con especificidad de unión para la seroalbúmina
AR104213A1 (es) Anticuerpos anti-cd38 como agentes terapéuticos
AR124676A2 (es) Formulación farmacéutica que comprende una droga biofarmacéutica
MX2022014631A (es) Proteinas de union triespecificas y/o trivalentes para la prevencion o el tratamiento de la infeccion por vih.
CY1122060T1 (el) Συνδυαστικη θεραπευτικη χρηση αντισωματων και ενδογλυκοσιδασεων
BR112019010265A2 (pt) anticorpos anti_cd137 inovadores e usos dos mesmos
AR103868A1 (es) Anticuerpos anti-cd47 como agentes terapéuticos
MX389598B (es) Inhibidores bicíclicos condensados de la interacción de menina-mll.
NZ734892A (en) Amatoxin-antibody conjugates
EA201891186A1 (ru) Антитела, нейтрализующие вирус иммунодефицита человека
AR093803A1 (es) Composiciones y metodos de anticuerpos de marcaje de epo
PE20170665A1 (es) Anticuerpos anti-tau humanizados
CL2018003608A1 (es) Anticuerpo aislado o fragmento de unión a antígeno del mismo que se une específicamente interleucina-25 hjumana (il-2525); composición farmacéutica que lo comprende; uso de dicha composición farmacéutica para tratar una enfermedad o trastorno asociado con la actividad o expresión de il-25. (divisional solicitud 201700703)
EA201700181A1 (ru) Композиции аденозиндеаминазы-2 (ада-2), их варианты и способы использования
BR112016011025A2 (pt) polipeptídeos anticorpo e seus usos
MX2015016329A (es) Bloqueador de anticuerpo para la inactivacion de farmaco de proteina.
PE20161032A1 (es) Anticuerpos anti-tau(ps422) humanizados y metodos de utilizacion
PE20141149A1 (es) Anticuerpos monoclonales frente al inhibidor de la ruta del factor tisular (tfpi)

Legal Events

Date Code Title Description
FB Suspension of granting procedure